Resources Repository
-
ArticlePublication 2014Cost-Effectiveness of Female HPV Vaccination in 179 Countries: A PRIME Modelling Study
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), …
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), used to assess cost-effectiveness and health effects of vaccination of girls against HPV before sexual debut in terms of burden of cervical cancer and mortality. The PRIME models incidence according to proposed vaccine efficacy against HPV 16/18, vaccine coverage, cervical cancer incidence and mortality, and HPV type distribution. It assumes lifelong vaccine protection and no changes to other screening programs…
Latin America & Caribbean | Sub-Saharan Africa | Health Systems | Health Outcomes | Mathematical Models | Calibration/Validation | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Health/Medicine | Global | Middle East & North Africa | Asia & Pacific -
GuidelinesPublication 2013Economic Analyses to Support Decisions about HPV Vaccination in Low- and Middle-Income Countries: Consensus Report and Guide
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability …
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability before introducing a program for human papillomavirus (HPV) vaccination. However, many such countries lack the technical capacity and data to conduct their own analyses. This report describes the consensus of an expert group convened by the World Health Organization, prioritizing key issues to be addressed when considering economic analyses to support HPV vaccine introduction in these countries. The expert group…
Latin America & Caribbean | Sub-Saharan Africa | Health Systems | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Economics/Finance | Health/Medicine | Science/Technology | Middle East & North Africa | Asia & Pacific -
ArticlePublication 2010Clinical Benefits, Costs, and Cost-Effectiveness of Neonatal Intensive Care in Mexico
This article reports on a study to estimate the clinical outcomes, costs, and cost-effectiveness of …
This article reports on a study to estimate the clinical outcomes, costs, and cost-effectiveness of neonatal intensive care in Mexico. The authors conducted a cost-effectiveness analysis using a decision analytic model of health and economic outcomes following preterm birth. Model parameters governing health outcomes were estimated from Mexican vital registration and hospital discharge databases, supplemented with meta-analyses and systematic reviews from the published literature. Costs were estimated on the basis of data provided by the…
Latin America & Caribbean | Health Systems | Child/Nutrition | State-Transition | Cost-Effectiveness Analysis | Clinical Care | Health/Medicine -
ArticlePublication 2010Health and Economic Impact of Rotavirus Vaccination in GAVI-Eligible Countries
Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately …
Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Motivated by the global recommendation by the WHO that all countries include infant rotavirus vaccination in their national immunization programs, the objective of this analysis was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. The authors synthesized population-level data from various sources (primarily from…
Latin America & Caribbean | Sub-Saharan Africa | Child/Nutrition | Health Outcomes | Mathematical Models | State-Transition | Cost-Effectiveness Analysis | Infectious Diseases | Economics/Finance | Health/Medicine | Middle East & North Africa | Asia & Pacific -
ArticlePublication 2023Out-of-Pocket Expenditures & Financial Risks Associated with Treatment of Vaccine-Preventable Diseases in Ethiopia
This study investigates out-of-pocket (OOP) expenditures and associated catastrophic health expenditures (CHEs) for vaccine-preventable diseases …
This study investigates out-of-pocket (OOP) expenditures and associated catastrophic health expenditures (CHEs) for vaccine-preventable diseases (VPDs) in Ethiopia. Through a cross-sectional costing analysis, data on OOP direct medical and nonmedical expenditures were collected from 995 households in 54 health facilities nationwide. The study focuses on VPDs in children under 5 years for pneumonia, diarrhea, measles, and pertussis, and in children under 15 years for meningitis. Mean OOP expenditures per disease episode ranged from $5·6 to…
Sub-Saharan Africa | Child/Nutrition | Costing Methods | Mathematical Models | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine -
ArticlePublication 2023Estimated Travel Time & Staffing Constraints to Accessing the Ethiopian Healthcare System: Two-Step Floating Catchment Area Analysis
This study investigates disparities in health care access across different income levels and geographic locations …
This study investigates disparities in health care access across different income levels and geographic locations in Ethiopia. Employing a two-step floating catchment area method, the research estimates variations in spatial access to health care and staffing levels at facilities. Average travel time from population centers is calculated and adjusted with provider-to-population ratios. Spearman's rank tests are applied to test hypotheses about the roles of travel time versus staffing in access variations. Results reveal regional disparities,…
Sub-Saharan Africa | Health Systems | Health/Medicine -
ArticlePublication 2022WHO ACTION-I Trial in Low Resource Countries
This study evaluated the cost-effectiveness of dexamethasone administration in dexamethasone in pregnant women at risk …
This study evaluated the cost-effectiveness of dexamethasone administration in dexamethasone in pregnant women at risk of early preterm birth using data from a multicentre, randomized, placebo-controlled trial in Bangladesh, India, Kenya, Nigeria, and Pakistan. Primary cost data were collected in 28 hospitals across the 5 countries. A decision tree model was used to compare dexamethasone treatment to no intervention from a health-care sector perspective. Administration of dexamethasone averted 38 neonatal deaths per 1000 woman–baby units…
Sub-Saharan Africa | Child/Nutrition | Health Outcomes | Mathematical Models | Cost-Effectiveness Analysis | Maternal/Reproductive Health | Clinical Care | Global | Asia & Pacific -
ArticlePublication 2014Step-by-Step Guideline for Disease-Specific Costing Studies in LMIC
Disease-specific costing studies can be used as input into cost-effectiveness analyses and provide important information …
Disease-specific costing studies can be used as input into cost-effectiveness analyses and provide important information for efficient resource allocation. This paper provides a step-by-step guideline for conducting disease-specific costing studies in LMICs where data availability is limited and illustrates how the guideline was applied in a costing study of cardiovascular disease prevention care in rural Nigeria. The step-by-step guideline provides practical recommendations on methods and data requirements for six sequential steps: 1) definition of the study…
Sub-Saharan Africa | Health Systems | Costing Methods | Chronic Disease/Risk | Health/Medicine -
ArticlePublication 2022Healthcare Cost of Overweight & Obesity in South Africa
This analysis estimates the healthcare cost associated with treatment of weight-related conditions from the perspective …
This analysis estimates the healthcare cost associated with treatment of weight-related conditions from the perspective of the South African public sector payer. The authors report that the total cost of overweight and obesity is estimated to be ZAR33,194 million in 2020, representing approximately 15% of government health expenditure and equivalent to 0.67% of GDP. This analysis is an example of a bottom-up gross costing approach. The study draws South African data from multiple sources to estimate…
Sub-Saharan Africa | Health Systems | Costing Methods | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine